Hangzhou, China

Qiaojun He

USPTO Granted Patents = 5 


 

Average Co-Inventor Count = 4.9

ph-index = 1

Forward Citations = 1(Granted Patents)


Location History:

  • Zhejiang, CN (2018 - 2019)
  • Hangzhou, CN (2022)

Company Filing History:


Years Active: 2018-2022

Loading Chart...
Loading Chart...
Loading Chart...
5 patents (USPTO):

Title: Innovations and Contributions of Qiaojun He

Introduction

Qiaojun He is a prominent inventor based in Hangzhou, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of antitumor drugs. With a total of five patents to his name, his work has the potential to impact cancer treatment significantly.

Latest Patents

One of Qiaojun He's latest patents is focused on the use of canagliflozin in the preparation of an antitumor drug. This invention highlights the significant down-regulation effect of canagliflozin on the immune checkpoint protein PD-L1 in various tumor cells. It has been shown to enhance the killing effect of T cells on tumor cells, broadening the clinical application of canagliflozin in tumor immunotherapy. Another notable patent involves a polyfluoro-substituted aromatic heterocyclic derivative, which demonstrates strong proliferation inhibitory activity against various cancer cell lines. This compound may serve as an Akt inhibitor in medications for treating solid tumors or blood cancers.

Career Highlights

Qiaojun He has worked with prestigious institutions such as Zhejiang University and the Chinese Academy of Sciences. His research and innovations have positioned him as a key figure in the pharmaceutical industry, particularly in cancer research.

Collaborations

He has collaborated with notable colleagues, including Bo Yang and Yongzhou Hu, contributing to the advancement of research in his field.

Conclusion

Qiaojun He's innovative work in the development of antitumor drugs showcases his commitment to improving cancer treatment. His patents reflect a deep understanding of pharmaceutical science and a dedication to advancing medical research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…